-
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
- September 7, 2026
- Posted by: Victoria Reynolds
- Category: Economics
No Comments
Interim MASTRR Registry analysis represents, to Aroa’s knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstructionAUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ — Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced…
-
Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
- September 7, 2026
- Posted by: Megan Foster
- Category: Business plans
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026 /PRNewswire/ — Today, shares of Harbour BioMed (the “Company”; HKEX: 02142.HK) were officially included in the eligible shares list of the Stock Connect. Effective immediately, qualified investors in mainland…
-
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
- September 6, 2026
- Posted by: Victoria Reynolds
- Category: Economics
— Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection —- Robust neutralizing antibody responses across…